Free tool
FAERS Monitor: Tasigna
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022068 or its brand name (Tasigna, Nilotinib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
29,425
Serious
21,731
74% of reports
Hospitalization
6,487
Death reported
5,641
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3,231
- fatigue2,112
- rash1,654
- nausea1,546
- headache1,494
- dyspnoea1,395
- pain1,344
- diarrhoea1,222
- drug ineffective1,210
- malaise1,143
- pruritus1,134
- pyrexia1,134
- arthralgia1,092
- asthenia1,065
- vomiting1,064
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 10 |
| 2008 | 254 |
| 2009 | 340 |
| 2010 | 450 |
| 2011 | 955 |
| 2012 | 1,851 |
| 2013 | 1,549 |
| 2014 | 2,183 |
| 2015 | 2,111 |
| 2016 | 2,531 |
| 2017 | 1,984 |
| 2018 | 2,275 |
| 2019 | 2,686 |
| 2020 | 2,319 |
| 2021 | 2,175 |
| 2022 | 1,821 |
| 2023 | 1,545 |
| 2024 | 1,084 |
| 2025 | 748 |
| 2026 | 554 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,024,734 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rashSignal | 1,654 | 2.7 | 2.6 | 1,827 |
| deathSignal | 3,231 | 2.7 | 2.6 | 3,553 |
| pyrexiaSignal | 1,134 | 2.3 | 2.2 | 887 |
| pruritusSignal | 1,134 | 2.1 | 2.0 | 674 |
| astheniaSignal | 1,065 | 2.0 | 1.9 | 562 |
| fatigue | 2,112 | 1.9 | 1.9 | 998 |
| arthralgia | 1,092 | 1.9 | 1.8 | 456 |
| malaise | 1,143 | 1.9 | 1.8 | 466 |
| dyspnoea | 1,395 | 1.8 | 1.7 | 472 |
| headache | 1,494 | 1.7 | 1.6 | 447 |
| vomiting | 1,064 | 1.6 | 1.5 | 256 |
| pain | 1,344 | 1.6 | 1.5 | 281 |
| nausea | 1,546 | 1.4 | 1.3 | 180 |
| diarrhoea | 1,222 | 1.4 | 1.3 | 116 |
| drug ineffective | 1,210 | 0.7 | 0.6 | 232 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.